APN News

  • Saturday, September, 2020| Today's Market | Current Time: 11:04:39
  • China Has Become Multinational Biopharmas Hottest Destination

    Published on July 30, 2010

    Shanghai, (PressExposure): From 18th to 21st October this year, the heads of global technical operations and heads of manufacturing from major biopharmaceutical players are meeting in Shanghai at BioManufacturing World and Vaccine Manufacturing World conferences, hosted by IMAPAC.

    This was driven by the recent trend of localized biologics and vaccine manufacturing into China, the hottest destination for biomanufacturing investment.

    In 2009 alone, GlaxoSmithKline plc (GSK) announced a new Joint Venture with Shenzhen Neptunus Interlong Bio-Technique Co. Ltd to develop and manufacture influenza vaccines, GSK followed that with another Joint Venture with Walvax. Microbix and Novartis followed the same trend; Microbix announcing a joint venture with Hunan biopharmaceutical and Novartis an 85% acquisition of Zhejiang Tianyuan Bio-pharmaceutical Co., Ltd.

    Investments in biosimilars manufacturing and China based CMOs are not exceptions. Cipla went into joint venture with Chinese firm Desano to form Biomab, and Beijing based biologics CMO Autek Bio raised $100M US from venture capitals earlier this year.

    On top of all that, China’s ministry of health recently announced new GMP standards that are going to reshape the industry’s quality standards. Many companies in China are starting to upgrade their facilities to meet the new guidelines.

    Over 150 biopharmaceutical manufacturers including international players including Roche, Novartis, Sanofi Pasteur, Glaxosmithkline, Pfizer, Biogen Idec, Biovac Institute, CSL Biopharma, as well as domestic industry leaders such as Sinovac, Hisun Pharmaceuticals, Biomab will present at the event.

    Responding to the newest GMP changes, the event will also bring together experts from SFDA and NICPBP to address the most recent update of GMP guidelines and biological product quality control in China.

    As many multinationals come to China to seek manufacturing partners or looking for best location to build their next manufacturing site, BIoManufacturing World will also showcase leading CMOs and Bioparks in China.

    Featuring key speakers like Pat Yang, Head of Global Technical Operations of Roche Pharmaceuticals, Matthew Stober, Global head of Technical Operations of Novartis Vaccines and Diagnostics, IMAPAC’s BioManufacturing World is where world biomanufacturing leaders gather to discuss best manufacturing strategies, share most cutting edge technologies and latest partnership models that will improve efficiency, product quality which will eventually drive delivery of high quality and affordable biopharmaceutical drugs for China.